UBS Group
PHAS

UBS Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

UBS Group’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,830
Closed -$6K – 11609
2022
Q2 		$6K Buy
9,830
+8,248
+521% +$7.9K ﹤0.01% 8811
2022
Q1 		$2K Sell
1,582
-3,018
-66% -$4.89K ﹤0.01% 9790
2021
Q4 		$12K Buy
4,600
+3,600
+360% +$10.9K ﹤0.01% 8630
2021
Q3 		$3K Sell
1,000
-3,087
-76% -$10.3K ﹤0.01% 8897
2021
Q2 		$15K Sell
4,087
-4,063
-50% -$13.5K ﹤0.01% 7672
2021
Q1 		$28K Buy
8,150
+6,842
+523% +$27.8K ﹤0.01% 7080
2020
Q4 		$4K Buy
+1,308
New +$4.68K ﹤0.01% 7951
2020
Q3 		– Sell
-8,121
Closed -$37K – 8612
2020
Q2 		$37K Sell
8,121
-1,742
-18% -$7.71K ﹤0.01% 6125
2020
Q1 		$33K Sell
9,863
-8,196
-45% -$37.5K ﹤0.01% 6150
2019
Q4 		$110K Buy
18,059
+5,139
+40% +$21.2K ﹤0.01% 5956
2019
Q3 		$54K Buy
12,920
+9,506
+278% +$75.8K ﹤0.01% 6163
2019
Q2 		$45K Buy
3,414
+1,669
+96% +$20.5K ﹤0.01% 6016
2019
Q1 		$17K Buy
+1,745
New +$6.91K ﹤0.01% 6451

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PTP
Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

UBS Group's PHAS Position: Q3 2022 in Review

UBS Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 9,830 shares — an estimated $6K sold.

UBS Group first reported a position in PHAS in Q1 2019 and held it in 13 quarters. The position peaked at $110K in Q4 2019. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

  • UBS Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • UBS Group sold 9,830 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $6K.
  • UBS Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • UBS Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $110K in Q4 2019.
  • 38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.